Zura Bio develops antibody medicines for autoimmune and inflammatory diseases, and has no approved products yet. In the past 30 days there were 4 dark pool prints.
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 12 | Wedbush | Target raised | Buy | |
| Aug 12 | Guggenheim | Maintained | Buy | |
| Jul 1 | Wedbush | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in ZURA in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZURA is in one of them and how their past ZURA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZURA in an article yet. Here's the latest on the wider market.
About Zura Bio
Zura Bio is a biotechnology company based in La Jolla, California, that develops antibody medicines for people with autoimmune and inflammatory diseases. Its tibulizumab candidate is designed to block two immune signals, IL-17A and BAFF, within a single molecule. The company also has crebankitug and torudokimab, which target other immune pathways. Tibulizumab is in two Phase 2 trials, in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, and no Zura Bio medicine is yet approved for sale.
- Headquarters
- La Jolla, CA